Bio-Path Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bio-Path stock.
View analyst ratings for Bio-Path or view top-rated stocks.

Wall Street analysts have given Bio-Path a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bio-Path wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Bio-Path.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) released its quarterly earnings results on Friday, May, 14th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.07.
View Bio-Path's earnings history.

Bio-Path's stock was trading at $4.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BPTH shares have increased by 36.4% and is now trading at $6.48.
View which stocks have been most impacted by COVID-19.

Shares of Bio-Path reverse split before market open on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

2 brokerages have issued 1 year price objectives for Bio-Path's stock. Their forecasts range from $12.00 to $13.00. On average, they anticipate Bio-Path's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 92.9% from the stock's current price.
View analysts' price targets for Bio-Path or view top-rated stocks among Wall Street analysts.

Some companies that are related to Bio-Path include Satsuma Pharmaceuticals (STSA), SELLAS Life Sciences Group (SLS), ObsEva (OBSV), Equillium (EQ), Matinas BioPharma (MTNB), PhaseBio Pharmaceuticals (PHAS), Anebulo Pharmaceuticals (ANEB), Lantern Pharma (LTRN), Abeona Therapeutics (ABEO), Tyme Technologies (TYME), AcelRx Pharmaceuticals (ACRX), Novan (NOVN), Assembly Biosciences (ASMB), Oasmia Pharmaceutical AB (publ) (OASMY) and Actinium Pharmaceuticals (ATNM).
View all of BPTH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), (CGC), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

Bio-Path's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.06%), Geode Capital Management LLC (0.81%), Morgan Stanley (0.57%), Citadel Advisors LLC (0.30%), Citadel Advisors LLC (0.30%) and Dimensional Fund Advisors LP (0.26%).
View institutional ownership trends for Bio-Path.

BPTH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Bio-Path or view top insider-selling stocks.

BPTH stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Geode Capital Management LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Bio-Path or or view top insider-buying stocks.

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BPTH stock can currently be purchased for approximately $6.48.

Bio-Path has a market capitalization of $45.10 million. The company earns $-10,880,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

Bio-Path employs 10 workers across the globe.

The official website for Bio-Path is www.biopathholdings.com.

Bio-Path is headquartered at 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401.

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]